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Abstract
Background and Objectives Cytochrome P450 2C9
(CYP2C9) is involved in the biotransformation of many
commonly used drugs, and significant drug interactions
have been reported for CYP2C9 substrates. Previously
published physiologically based pharmacokinetic (PBPK)
models of tolbutamide are based on an assumption that its
metabolic clearance is exclusively through CYP2C9;
however, many studies indicate that CYP2C9 metabolism
is only responsible for 80–90% of the total clearance.
Therefore, these models are not useful for predicting the
magnitude of CYP2C9 drug–drug interactions (DDIs). This
paper describes the development and verification of
SimCYP-based PBPK models that accurately describe the
human pharmacokinetics of tolbutamide when dosed alone
or in combination with the CYP2C9 inhibitors sul-
faphenazole and tasisulam.
Methods A PBPK model was optimized in SimCYP for
tolbutamide as a CYP2C9 substrate, based on published
in vitro and clinical data. This model was verified to
replicate the magnitude of DDI reported with sul-
faphenazole and was further applied to simulate the DDI
with tasisulam, a small molecule investigated for the
treatment of cancer. A clinical study (CT registration #
NCT01185548) was conducted in patients with cancer to
assess the pharmacokinetic interaction of tasisulum with
tolbutamide. A PBPK model was built for tasisulam, and
the clinical study design was replicated using the optimized
tolbutamide model.
Results The optimized tolbutamide model accurately pre-
dicted the magnitude of tolbutamide AUC increase
(5.3–6.2-fold) reported for sulfaphenazole. Furthermore,
the PBPK simulations in a healthy volunteer population
adequately predicted the increase in plasma exposure of
tolbutamide in patients with cancer (predicted AUC
ratio = 4.7–5.4; measured mean AUC ratio = 5.7).
Conclusions This optimized tolbutamide PBPK model was
verified with two strong CYP2C9 inhibitors and can be
applied to the prediction of CYP2C9 interactions for novel
inhibitors. Furthermore, this work highlights the utility of
mechanistic models in navigating the challenges in con-
ducting clinical pharmacology studies in cancer patients.
Key Points
A mechanism-based PBPK model is described for the
prediction of CYP2C9-related drug interactions with
tolbutamide. The model was verified with clinical data
from the literature (sulfaphenazole) and from a drug
interaction study with tasisulam in patients with cancer.
This optimized tolbutamide PBPK model can be
applied to the prediction of CYP2C9 interactions for
novel inhibitors.
1 Introduction
Cytochrome P450 2C9 (CYP2C9) is a polymorphic enzyme
responsible for themetabolism ofmany frequently used drugs,
including warfarin, phenytoin, celecoxib, and sulfonylureas
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[1, 2]. CYP2C9 expression is third highest among hepatic
CYPs, accounting for an average of approximately 13% of the
total CYP protein measured in human liver microsomes [3].
Individuals exhibiting the CYP2C9 poor metabolizer pheno-
type can be at increased risk of adverse events with drugs such
as warfarin, and they often require lower doses of CYP2C9
substrates to be effective yet safe. Clinically significant drug–
drug interactions (DDIs) have also been observed with
CYP2C9 substrates, warfarin and phenytoin both being listed
as narrow therapeutic index substrates [4].
Because of the potential effect of DDIs on the safety and
efficacy of drugs, accurate prediction of potential drug
interactions and pharmacogenetic effects for CYP sub-
strates and inhibitors is important in drug development.
Physiologically based pharmacokinetic (PBPK) modelling
is increasingly applied for quantitative prediction of the
pharmacokinetic effects of drug interactions and inter-in-
dividual variation. To this end, the commonly used soft-
ware SimCYP Simulator provides many predefined
substrate and inhibitor models, with varying degrees of
external verification. It is, however, important to continu-
ally reassess and modify PBPK models as additional
physiological, in vitro, and clinical data become available.
It is likewise important to verify such models for their
intended purpose [5]. For example, it has been shown that
PBPK models for patients with hepatic impairment have
not been sufficiently developed, and physiologically based
absorption models for neonates and infants need extensive
verification [6, 7]. PBPK modelling has proven to be
especially useful in oncology applications, where standard
clinical pharmacology trials are not always feasible. In this
manuscript, the development of a mechanistically based
PBPK model for tolbutamide is described and verified for
use in DDI prediction with two strong CYP2C9 inhibitors.
Tolbutamide is a first-generation oral sulfonylurea used
for the treatment of people with diabetes since the 1950s
[8, 9]. It is metabolized by CYP2C9 and is subject to drug
interactions with CYP2C9 inhibitors [10]. Tolbutamide
PBPK models have been used previously to verify inter-
system extrapolation factors (ISEFs) for recombinant
enzymes and to accurately model the effect of polymorphic
enzyme expression in Chinese and Caucasian populations
[11, 12]. However, these models assumed that tolbutamide
clearance was completely dependent on hepatic CYP2C9,
and did not evaluate the effect of enzyme inhibition. The
current SimCYP-provided sim-tolbutamide substrate
model utilizes unique enzyme kinetic parameters for
tolbutamide clearance. This default tolbutamide model has
been partially characterized, with modifications described
to better predict pharmacokinetics observed in Chinese
individuals [11]. However, there are no published examples
of accurate modelling of significant CYP2C9-related
tolbutamide drug interactions using SimCYP.
Tasisulam is a novel anti-cancer agent that showed
potential anti-angiogenic activity across a range of tumor
types in animal and in vitro models. It was previously
investigated in Phase II clinical studies in patients with
melanoma, soft tissue sarcoma, and non-small cell lung
cancer, but further development of this molecule has been
terminated because of insufficient clinical benefit [13–17].
Tasisulam is highly bound to albumin ([99.7%) and has a
long terminal half-life (11 days) that approximates the
half-life of circulating albumin [18]. In vitro studies
showed tasisulam competitively inhibits CYP2C9, and
could therefore affect the clearance and metabolism of
sensitive CYP2C9 substrates, such as warfarin and tolbu-
tamide [19].
The effect of tasisulam as an inhibitor of CYP2C9 on the
clearance of tolbutamide was evaluated in a small Phase I
study in patients with cancer, which is described in this
report. However, the conduct of clinical pharmacology
studies in patients with cancer patients is challenging, due
to their health concerns, frequent concomitant medications,
and issues around enrolment. As PBPK models are
increasingly accepted by regulatory agencies as alterna-
tives to clinical studies, further verification of the use of
these models in specific disease states is needed [4, 5, 20].
This paper describes the optimization and verification of a
mechanistically based middle-out PBPK model for tolbu-
tamide based on published in vitro and in vivo studies, and
then demonstrates the ability of the refined SimCYP
model to accurately predict tolbutamide interactions with
both oral sulfaphenazole and intravenous tasisulam. These
data support that this verified PBPK model can be suc-
cessfully applied to predict interactions for other CYP2C9
inhibitors.
2 Methods
2.1 PBPK Simulations
All PBPK simulations were performed using PKPD pro-
files mode in SimCYP SimulatorTM (v.15). Trial simu-
lations were conducted using a 10 trial 9 10 subject
design, with a healthy volunteer population (age 20–50;
proportion of females = 0.5) in the fasted state. All indi-
viduals in the population were set to be CYP2C9 extensive
metabolizers to match the clinical studies. Default
SimCYP parameters were employed for models except
where specifically noted.
2.1.1 Tolbutamide
A tolbutamide PBPK model was built using SimCYP
based on the Sim-tolbutamide model file with
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modifications. Model input parameters are listed in
Table 1. The fraction metabolized (fm) was estimated to be
approximately 0.85, based on published clinical and
in vitro data [10, 21–24]. The CYP2C9 unbound intrinsic
clearance was back-calculated from the IV clearance using
the retrograde calculator in SimCYP, resulting in a value of
0.065 lL/min/pmol of CYP isoform. A non-CYP2C9
hepatic metabolism clearance pathway was included in the
elimination parameters to estimate approximately 15% of
the total clearance.
2.1.2 Sulfaphenazole–Tolbutamide Interaction
To assess the predictive ability of the optimized tolbu-
tamide model as a ‘‘victim’’ compound for DDIs, interac-
tion studies were simulated utilizing the tolbutamide PBPK
model described above and the default sim-sulfaphenazole
model (Table 1). Performance verification has been con-
ducted for the sim-sulfaphenazole model by Certara using
published clinical data [25, 26]. In the interaction,
sulfaphenazole was defined as the CYP2C9 perpetrator and
tolbutamide as the victim. Interaction simulations were
conducted with the dosing paradigm previously described
by Veronese et al., and the data from that study were used
to verify the PBPK model [27]. Briefly, the trial design
included a single tolbutamide dose administered 24 h after
initiating sulfaphenazole dosing at 2000 mg every 12 h.
Sulfaphenazole dosing continued for 4 days following
tolbutamide administration. The trial duration was set to
20 days to capture the complete plasma concentration–time
profile and 10,000 samples per individual were simulated.
2.1.3 Tasisulam
A minimal PBPK model was created for tasisulam using a
combination of in vitro and clinically derived and predicted
input values (Table 2). The dose of infused tasisulam was
set at 40 mg/kg and the infusion time to 2 h, approximating
the dosing schedule of the JZAR clinical study described
below. The plasma clearance of tasisulam was based on
Table 1 Tolbutamide and sulfaphenazole PBPK input parameters
Parameter Source
Model Tolbutamide Sim-sulfaphenazole
Molecular weight (g/mol) 270.3 314.36 SimCYP Default
LogP 2.34 1.52 SimCYP Default
pKa 5.27 5.91 SimCYP Default
Blood to plasma ratio 0.6 0.62 SimCYP Default
fu 0.044 0.028 SimCYP
 Default
Fa 1 1 SimCYP Default
ka (h
-1) 0.52 1.86 SimCYP Default
hPeff (910-4 cm/s) 0.95 NA SimCYP Default
Hydrogen bond donors 2 2 SimCYP Default
PSA (A2) 83.65 98.39 SimCYP Default
fuGut 1 0.0275 SimCYP
 Default
Vdss (L/kg) 0.105 0.162 SimCYP
 Default
CLpo (L/h) NA 0.382 SimCYP
 Default
CLrenal (L/h) 0
a 0.084 b
Distribution model Minimal PBPK Minimal PBPK SimCYP Default
CYP2C9 CLint (lL/min/pmol isoform) 0.065 NA Retrograde calculation based on
an assumed CYP2C9 fm of 0.85
Additional HLM CL (lL/min/mg protein) 0.8 NA Retrograde calculation based
on an assumed CYP2C9 fm of 0.85
Ki CYP2C9 (lM) NA 0.16 SimCYP Default
fumic 1.0
c 0.972b
LogP partition coefficient, pKa acid dissociation constant, fu fraction unbound in plasma, Fa fraction absorbed, ka absorption rate constant, hPeff
effective permeability in humans, NA not applicable, PSA polar surface area, fuGut fraction unbound in gut, Vdss volume of distribution at steady
state, CLpo oral clearance, CLint intrinsic clearance, HLM CL human liver microsomal clearance, Ki inhibition constant, fumic fraction unbound in
microsomes, PBPK physiologically based pharmacokinetic
aSet to zero
bSimCYP Default
cCarlile et al. [51]
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observed clearance in patients. A single adjusting com-
partment (SAC) was included in the model to better capture
the Cmax and initial rapid distribution phase of tasisulam.
The volume of distribution at steady state (Vdss) was
derived from clinical plasma concentration time profiles,
using the Nelder–Mead minimization method and weigh-
ted-least squares as the objective function [28]. The values
for the volume of distribution in the SAC and the intra-
compartmental clearance (Q) were derived from the pop-
ulation pharmacokinetic analysis of tasisulam (unpublished
data).
2.1.4 Tasisulam–Tolbutamide Interaction
Drug interaction trials were simulated utilizing the opti-
mized tolbutamide and tasisulam PBPK models. The
interaction was set at CYP2C9 with tasisulam as the per-
petrator and tolbutamide as the victim, using the unad-
justed measured inhibition constant (Ki) and predicted
fraction unbound in the microsomes (fumic) shown in
Table 2. The interaction simulations were conducted with
the dosing paradigm used in periods 2 and 3 of the JZAR
study, described below. A fixed dose of 40 mg/kg and 2-h
intravenous infusion of tasisulam was used to approximate
the individualized dosing from this study. To simulate the
acute interaction (Period 2), a 500 mg oral dose of tolbu-
tamide was introduced 2 h prior to the start of the tasisulam
infusion. Simulation of the potential sustained effect of
inhibition by tasisulam (Period 3) was conducted by
introducing the 500 mg tolbutamide dose 72 h after the
start of the tasisulam infusion. The total duration of the trial
simulations was 15 days, to adequately capture the AUC in
the inhibited state.
2.2 In vitro Inhibition CYP2C9 by Tasisulam
The effect of tasisulam on CYP2C9 activity was assessed
in vitro by measuring the inhibition of diclofenac 40-hy-
droxylation in human liver microsomes. Incubation mix-
tures of approximately 500 lL contained human hepatic
microsomes (0.05 mg/mL protein) in 100 mM potassium
phosphate buffer (pH 7.4), 1 mM NADPH, and diclofenac
(0.5, 5, 10, 15, or 25 lM), in the absence or presence of
0.1, 0.5, 1, or 2.5 lM tasisulam as inhibitor. Following
4-min incubations at 37 C, quenched incubations were
analyzed for the formation of 40-hydroxydiclofenac by LC–
MS/MS. 40-Hydroxydiclofenac was obtained from Gentest
Corporation (Woburn, MA, USA), diclofenac from Sigma
Chemical Company (St. Louis, MO, USA) and human
hepatic microsomes from CEDRA Corporation (Austin,
TX, USA); all other reagents were purchased from com-
mercial vendors.
Microsomal protein binding (fumic) of tasisulam was
estimated to be 0.31 using a proprietary quantitative
structure–property relationship (QSPR) in silico model.
This model was built based on the in vitro Fumic values for
7448 Eli Lilly library compounds, which were measured
using equilibrium dialysis at 1 lM. The Fumic values in this
training set ranged from 0.0001 to 1 (1st quartile—0.28;
median—0.54; 3rd quartile—0.72). The model was built
using the support vector machine algorithm incorporating
structural fingerprints [29], and the optimum fingerprint
Table 2 Tasisulam PBPK input
parameters
Parameter Value Source
Molecular weight (g/mol) 437.09
LogP 3.8 Measured in vitro
pKa 2.2 (acidic) Measured in vitro
Blood to plasma ratio 0.55 Estimated value for an acid
fu 0.003 Measured in vitro
Vdss (L/kg) 0.165 Gordon et al. [18]
VSAC (L/kg) 0.075 Fitted from JZAR
QSAC (L/h) 2.45 Fitted from JZAR
CL systemic (L/h) 0.025 From clinical study results
Ki CYP2C9 (lM) 0.1 Measured in vitro
fumic 0.31 Predicted with in-house QSAR model
Dosing route I.V. infusion Clinical data
Dose (mg/kg) 40 Clinical data
Dosing time (h) 2 Clinical data
LogP partition coefficient, pKa acid dissociation constant, fu fraction unbound in plasma, Vdss volume of
distribution at steady state, VSAC volume of single adjusting compartment, QSAC blood flow of single
adjusting compartment, CL clearance, Ki inhibition constant, fumic fraction unbound in microsomes, PBPK
physiologically based pharmacokinetic
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was identified as described previously by Desai et al. [30].
The model was evaluated using prospective validation
wherein the predicted vs. measured Fumic values were
compared for an additional 544 internal compound test set
measured after the model was constructed. In this assess-
ment, the predicted Fumic values were within twofold of the
measured values for 78% compounds and within threefold
for 95%.
2.3 Study JZAR: Tasisulam-Tolbutamide
Interaction in Patients with Cancer
2.3.1 Eligibility Criteria
Study H8K-MC-JZAR (JZAR, ClincialTrials.gov Registry
# NCT01185548) was conducted in patients to evaluate the
effect of tasisulam on the pharmacokinetics of the
CYP2C9 probe substrate tolbutamide. Eligible patients
must have had histologically or cytologically confirmed
solid malignancy or lymphoma with advanced and/or
metastatic disease that was unresponsive to standard ther-
apies and an ECOG scoreB 1. All patients had discontin-
ued previous cancer therapies at least 30 days prior to
enrolment and had recovered from any toxicities. Patients’
serum albumin levels were required to beC 30 g/L (actual
range = 39–48 g/L). Patients with documented brain
metastases, leukemia, diabetes mellitus, and those receiv-
ing warfarin were excluded as were patients being treated
with sulfonylureas. The severity of adverse events was
assessed using the National Cancer Institute CTCAE ver-
sion 4.02 [31].
2.3.2 Study Design: Tasisulam Dosing
and Pharmacokinetics
Tasisulam was supplied as a sterile, lyophilized powder for
IV infusion after reconstitution to a concentration of
50 mg/mL in sterile water and administered as an IV
infusion over 2 h on Day 1 of a 28 day cycle. To provide
an intravenous tasisulam dose within the exposure range
that likely offered the best balance of efficacy and toxicity,
a dosing-calculator that incorporated lean-body weight and
pre-dose plasma albumin concentration was used in clinical
trials [17, 18]. In Cycle 1, a loading dose of tasisulam was
administered followed by continued dosing in subsequent
cycles that was either 65 or 75% of the loading dose,
depending on pre-cycle albumin levels.
Study JZAR was an open-label, fixed sequence, 3-period
study. The CYP2C9 metabolizer status was determined for
each patient. In each period, patients fasted for at least 8 h
prior to dosing (except for water) and until at least 2 h after
administration. To avoid cases of hypoglycaemia, all
patients received 100 g of oral glucose 1 h after each dose
of tolbutamide. In Period 1, patients received 500 mg
tolbutamide orally on Day 1, with an 8 day washout prior
to starting Period 2. Periods 2 and 3 were 28 day cycles,
with a single intravenous dose of tasisulam administered on
Day 1. In Period 2, patients received a 500 mg dose of
tolbutamide orally, and then 2 h after tolbutamide admin-
istration they received a 2-h infusion of an individualized
loading dose of tasisulam (as described above). The timing
of administration of tolbutamide was selected so that the
tolbutamide Tmax (approximately 4 h) coincided with that
of tasisulam (i.e. end of infusion). In Period 3, the persis-
tence of any potentially clinically relevant inhibitory
effects of tasisulam on CYP2C9 after 72 h was assessed by
evaluating the pharmacokinetics of tolbutamide following
a single 500-mg dose that was given 72 h after the
tasisulam dose. Blood samples of approximately 2 mL
were collected in Periods 1, 2, and 3 to determine the
plasma concentrations of tolbutamide and tasisulam at the
following times relative to the dosing (oral or start of
infusion) of the respective drug:
2.4 Tolbutamide
Period 1: Pre-dose; and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 24, 48,
and 72 h.
Period 2: Pre-dose; and 0.5, 1, 1.5, 2, 2.5, 3, 4, 4.5, 5, 6,
8, 24, 48, 72, 120, 168, 336 h.
Period 3: Pre-dose; and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 24,
48, 96, and 264 h.
2.5 Tasisulam
Period 2: Pre-infusion start; and 0.5, 1, 2, 2.5, 3, 4, 6, 22,
46, 70, 118, 166, and 334 h.
Period 3: Pre-infusion start; and 1, 2, 2.5, 3, 4, 6, 48, 72,
72.5, 73, 73.5, 74, 74.5, 75, 76, 78, 80, 96, 120, 168, and
336 h.
Following the drug interaction evaluation (Periods 1–3),
patients could continue to receive tasisulam, at an indi-
vidualized continuing dose, in 28 day cycles until evidence
of disease progression, unacceptable toxicity or failure to
meet minimum albumin levels required for dosing at which
point the patients discontinued the study.
2.5.1 Bioanalytical Methods
All bioanalytical determinations of tasisulam and tolbu-
tamide concentrations were conducted at Advion Bioser-
vices, Inc., Ithaca, NY, USA. Plasma samples were
analyzed for tasisulam concentrations using validated LC/
MS/MS methods for both high and low concentration
ranges [32]. For the low range, the upper (ULQ) and lower
limits of quantitation (LLQ) were 5 and 0.025 lg/mL,
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respectively; for the high range, the ULQ and LLQ were
500 and 2.5 lg/mL, respectively. Tolbutamide plasma
concentration was quantified using a validated LC/MS/MS
method. The LLQ was 1 ng/mL and the ULQ was 500 ng/
mL.
2.5.2 Pharmacokinetic Analysis Methods
Pharmacokinetic parameters were determined from plasma
concentrations using standard non-compartmental analysis
techniques in WinNonlin (version 5.2; Certara, Princeton,
NJ, USA). A mixed-effects model was used to analyze the
log-transformed tolbutamide AUC(0–inf) and Cmax. The
model contained treatment (tolbutamide [reference],
tolbutamide? tasisulam [test]); as the fixed effect and
patient as a random effect. From the model, least squares
mean (LSMean) and the 90% CI for the difference of
means were estimated, then transformed back to the orig-
inal scale to estimate the ratio of geometric means and 90%
CI for the comparison (tolbutamide? tasisulam versus
tolbutamide alone). A nonparametric analysis of Tmax was
performed using the Wilcoxon signed rank test. Median
differences between the treatments were calculated using
the Hodges–Lehmann method. All calculations were per-
formed using SAS software 9.1.
3 Results
3.1 Tolbutamide and Sulfaphenazole PBPK
PBPK simulations were conducted to evaluate the accuracy
of predicting CYP2C9 DDI using tolbutamide as a sub-
strate. Initial simulations using the default sim-tolbutamide
and sim-sulfaphenazole input files dramatically over-pre-
dicted the reported AUC0–inf ratio of approximately 5, with
a mean predicted AUC ratio of[27 (data not shown).
Therefore, a revised model was built with elimination
parameters to better represent the current mechanistic
understanding of tolbutamide clearance, as described in the
Methods. The retrograde calculation function in SimCYP
was used to estimate the CYP2C9 Clint, with an additional
nonspecific clearance pathway added to approximate the
reported in vitro and in vivo observations. The resulting
average fraction of tolbutamide metabolized (fm) by
CYP2C9 was 0.81 in the overall simulated population. The
sulfaphenazole interaction was then simulated to verify the
optimized model, resulting in good reproduction of the
reported tolbutamide pharmacokinetic parameters
(Table 3; Fig. 1) in both inhibited and uninhibited states.
The predicted AUC ratio of 5.7 was in line with that of 5.3
previously reported by Veronese [27]. A mean Cmax value
for tolbutamide was not reported from that clinical study;
however, digitization of the representative plasma con-
centration curve included in the manuscript suggests values
of approximately 39 and 52 mg/L in the uninhibited and
inhibited states, respectively. Again, this is consistent with
the simulated geometric mean Cmax values of 39 and
53 mg/L in the uninhibited and inhibited states, respec-
tively (Table 3).
3.2 Pharmacokinetics
3.2.1 Study JZAR Patient Characteristics
Four patients, one each with primary hepatic, renal, duo-
denal and esophageal cancer, received at least one dose of
tolbutamide. The patients, three men and one woman, had
ages ranging between 44 and 71 years. The mean weight
was 73.2 kg (range 63.6–81.4). Only two patients com-
pleted the third period of the study. No CYP2C9 poor
metabolizers enrolled in the study; all patients had *1/*1
alleles.
3.2.2 Tasisulam
Figure 2 shows the mean plasma concentration versus time
profiles in Period 2 and Table 4 summarizes the pharma-
cokinetic parameters of tasisulam from study JZAR, when
intravenously infused over 2 h. Following the end of
infusion, plasma concentrations of tasisulam appeared to
decline in a bi-phasic manner, with a long mean terminal
half-life (t1/2) values of 248–274 h. Likewise, the average
clearance of tasisulam was slow and volume of distribution
(Vz) low, at approximately 0.02 L/h and 6.6–8.3 L,
respectively. These values are in line with those previously
reported for tasisulam in patients with cancer [17, 18].
Although tasissulam concentrations were quantifiable prior
to dosing in Period 3, the tasisulam dosing algorithm
yielded similar plasma concentration–time curves and
pharmacokinetic parameters in Periods 2 and 3 (Table 4).
3.2.3 Tolbutamide
When tolbutamide was administered without tasisulam,
tolbutamide plasma concentrations appeared to decline in a
monophasic manner (Fig. 3, Table 5). Following co-ad-
ministration of tolbutamide with tasisulam in Periods 2 and
3, the T of tolbutamide was considerably longer, with
mean values of 43 and 35 h, respectively, compared to a
mean T of 7 h when administered alone (Period 1).
Individual tolbutamide t values ranged from 5 to 9, 34 to
55 and 29 to 42 h, respectively, for Periods 1, 2, and 3.
Apparent total plasma clearance of tolbutamide decreased
following tasisulam administration, with mean values
decreasing from 1.1 L/h in Period 1 to 0.19 L/h in Periods 2
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Table 3 Simulated and reported tolbutamide pharmacokinetics following an oral dose of 500 mg, alone or following multiple doses of 2000 mg
sulfaphenazole every 12 h
Tolbutamide Tolbutamide (? sulfaphenazole)
Simulated GM (%CV) Reported mean (SD) Simulated GM (%CV or CI) Reported mean (SD)
CLpo (L/h) 0.84 (62%) 0.86 (0.3)
a; 0.82 (0.11)b 0.15 (48%) 0.16 (0.04)b
Cmax (mg/L) 38.8 (35%) 39
#,b 53.0 (35%) 52#,b
AUC (mgh/L) 585 (53%) 586.8 (52.2)b 3359 (40%) 3100 (1044)b
AUC ratio NA NA 5.74 (5.3, 6.22) 5.3b
Cmax ratio NA AN 1.37 (1.33, 1.4) 1.33
#,b
SD standard deviation, CLpo oral clearance, Cmax maximal plasma concentration, AUC area under the curve, NA not applicable, GM geometric
mean, CV coefficient of variation
References: a[52]; b[27]
#Estimated from digitized graph of representative subject
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Fig. 1 Simulated and reported plasma concentration–time profiles of
tolbutamide alone (black) and in the presence of sulfaphenazole (red),
after an oral 500 mg dose in healthy subjects a linear and b log-linear
scale. Solid lines represents the predicted mean concentrations of
tolbutamide. Dotted lines represent the predicted 5th and 95th
percentiles. Solid squares represent the mean reported data from
Nordmark et al. [39]. The solid circles represent the mean plasma
concentrations from Madsen et al. [38]. The open circles and red
triangles represent the concentrations from Veronese et al. [27]. The
solid black triangles represent the mean concentrations from Dixit
and Rao [40]. c Simulated and reported plasma concentration–time
profiles of sulfaphenazole after a single oral 1000 mg dose. Solid
black line represents the predicted mean concentration of sul-
faphenazole. Dotted black lines represent the predicted 5th and 95th
percentiles. Solid circles represent reported data by Ries et al. [26].
d Simulated and reported plasma concentration–time profiles of
sulfaphenazole after an oral dose of 2000 mg followed by 500 mg
twice daily for 4 days. Solid black line represents the predicted mean
concentration of sulfaphenazole. Dotted black lines represent the
predicted 5th and 95th percentiles. Solid circles represent reported
data by Bunger et al. [25]
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and 3. In contrast, there appeared to be no change in the
apparent volume of distribution between periods. There-
fore, co-administration of tasisulam and tolbutamide
resulted in an increase in the systemic exposure
(AUC0–tlast) of tolbutamide (2650 mgh/L) in Period 2
compared to administration alone (467 mgh/L) in Period
1, with a ratio of Least Squared Means of 5.70 (90% CI
4.74, 6.86). The PK parameters for tolbutamide were very
similar in Period 2 and Period 3, confirming that the long
half-life of tasisulam resulted in prolonged inhibition (at
least 72 h) of CYP2C9. The Cmax for tolbutamide was
similar between periods (Table 5).
3.2.4 Clinical Safety
The most frequent treatment emergent adverse event was
dizziness, which occurred in two patients. One patient who
experienced dizziness 1.5 h into the tasisulam infusion in
Period 2 had a blood glucose at baseline of 83 mg/dL
(4.6 mmol/L) and by 1.5 h into the infusion this had fallen
to 59 mg/dL (3.3 mmol/L), but rose again within 5 min of
consuming food; this patient again experienced dizziness
on Day 9 of Period 2. The second patient experienced
dizziness on Day 13 of Period 2.
One patient had an AE of thrombocytopenia considered
related to study treatment that started in Period 2 as Grade
2 (Day 8), increased to Grade 3 (Day 9) and then Grade 4
(Day 10) before returning to Grade 2 (Day 12) and Grade 1
at follow-up (Day 32). All other AEs were Grade 1 or
Grade 2 and there were no deaths during the study. One
serious adverse event (CTCAE Grade 1 musculoskeletal
chest pain resulting in hospitalization) was reported that the
investigator considered unrelated to study treatment.
3.3 Tasisulam DDI Simulation
The PBPK model for tasisulam adequately reproduced in
simulated healthy subjects the plasma concentration–time
profiles of tasisulam observed in cancer patients (described
above) after an infusion of 40 mg/kg of tasisulam as seen
in Fig. 2. The model also reproduced Cmax and AUC values
in plasma, with predicted:observed ratios of 1.09 and 1.03,
respectively (Table 4). The observed plasma concentra-
tion-versus-time profile for tolbutamide in the presence and
absence of tasisulam are well described by the PBPK
models and the in vitro inhibition parameters. The corre-
sponding observed and predicted AUC and Cmax ratios of
tolbutamide in the presence of tasisulam are shown in
Table 5. All predicted values are within 20–25% from the
observed values.
4 Discussion
This paper describes the development and verification of a
SimCYPTM-based PBPK model that accurately describes
human pharmacokinetic drug interactions of tolbutamide,
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Fig. 2 Observed and predicted plasma concentration time profiles for
tasisulam (Study JZAR Period 2). Points represent the observed data.
Solid lines represent the predicted mean tasisulam concentration.
Dotted lines represent the predicted 5th and 95th percentiles of
simulation. Inset shows detail of early time points
Table 4 Simulated and
observed (Study JZAR)
tasisulam pharmacokinetics
following a 2-h intravenous
infusion of tasisulam
Tasisulam
Geometric mean (%CV or range)
Simulated Observed—Period 2 (N = 4) Observed—Period 3 (N = 2)
CL (L/h) 0.02 (32%) 0.02 (31%) 0.02
Cmax (mg/L) 409 (37%) 393 (9%) 403
AUC0–t (mgh/L) 70,417 (28%) 62,600 (11%) 68,200
Vz (L) NC 8.3 (16) 6.6
Tmax (h) 2 (2–2) 1.99 (1.93–2.00) 2.25 (2.00–2.50)
T1/2 (h) 287 (88–679) 274 (177–398) 248 (178–345)
%CV coefficient of variation, CL clearance, Cmax maximal plasma concentration, AUC0–t area under the
curve from 0 to last time point, NC not calculated, Vz volume of distribution, Tmax time of maximal
concentration, T1/2 half-life
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in this case when dosed alone or in combination with the
CYP2C9 inhibitors sulfaphenazole and tasisulam.
Tolbutamide is extensively metabolized in humans, with
85% of an oral dose excreted as metabolites in the urine
over 48 h [33]. Tolbutamide metabolism occurs predomi-
nantly through oxidation to 4-hydroxytolbutamide (4-HT),
which is further oxidized to carboxytolbutamide [34–36].
The initial rate-limiting hydroxylation step is catalyzed by
CYP2C9. As a result, tolbutamide exhibits polymorphic
pharmacokinetics and is affected by concomitant CYP2C9
inhibitors, such as sulfaphenazole [2, 22, 37]. Although
tolbutamide has been extensively studied, and is an FDA
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Fig. 3 a Observed and predicted plasma concentration–time profiles
of tolbutamide in the absence of tasisulam (Period 1, blue). Solid
points represent the observed tolbutamide data from study JZAR.
Solid lines represent the predicted mean concentration of tolbutamide.
Dotted lines represent the predicted 5th and 95th percentiles. Inset
shows detail of early time points. b Observed and predicted plasma
concentration–time profiles of tolbutamide in the presence of
tasisulam (Period 2, red). Solid points represent the observed
tolbutamide data from study JZAR. Solid lines represent the predicted
mean concentration of tolbutamide in the presence of tasisulam
(Period 2). Dotted lines represent the predicted 5th and 95th
percentiles. Inset shows detail of early time points. c Observed and
predicted plasma concentration–time profiles of Tolbutamide in the
presence of tasisulam (Period 3, green). Solid points represent the
observed tolbutamide data from study JZAR. Solid lines represent the
predicted mean concentration of tolbutamide in the presence of
tasisulam (Period 3). Dotted lines represent the predicted 5th and 95th
percentiles. Inset shows detail of early time points
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recommended in vivo substrate for investigating CYP2C9
DDI, relatively few clinical interaction studies have been
published, all of which were in healthy subjects [38–41].
One of the most significant tolbutamide interactions has
been observed with concomitant oral administration of
sulfaphenazole [27, 37, 42]. To assess the utility of PBPK
modelling to predict CYP2C9 DDI, an initial investigation
of the default SimCYP tolbutamide (sim-tolbutamide)
model was conducted using the software-provided param-
eters for tolbutamide and sulfaphenazole. The clinical trial
design described by Veronese et al. [27] was replicated in
SimCYP, but with a larger population of virtual subjects. In
this study, a single oral dose of tolbutamide (500 mg) was
administered to healthy volunteers following multiple
doses of sulfaphenazole. These simulations appeared to
adequately reproduce the individual plasma concentration
profiles for both drugs, but using these compound files in a
simulated interaction trial resulted in a more than fivefold
difference between predicted and reported clinical values.
This suggests that while the default sim-tolbutamide model
can reproduce the pharmacokinetics of tolbutamide alone,
the model’s high dependence on CYP2C9 for tolbutamide
clearance might be inaccurate.
The sim-tolbutamide model assumes CYP2C9 fm = 1,
but there are several lines of evidence suggesting that a
more accurate value is between 0.8 and 0.9. An early paper
reported that approximately 85% of an oral tolbutamide
dose was excreted as hydroxy- and carboxy-metabolites in
48 h by healthy human volunteers [33]. Similar results
were reported in 1990, with 51–96% of the dose excreted
as these two CYP2C9-dependent metabolites in 24 h [34].
A more recent 14C microdose study in healthy subjects also
produced similar findings of 77% of the radioactive dose
recovered in the urine of CYP2C9*1/*1 individuals as
these metabolites over 72 h [43]. The total recovery of the
14C microdose in this group was\85% and only about 1%
was recovered as parent tolbutamide in the urine, leaving
open the possibility that other minor metabolic pathways
are involved in its systemic clearance.
Multiple in vitro and computational approaches to
quantitatively assess the role of CYP2C9 in tolbutamide
clearance have also been described, which together indi-
cate an fm in the range of 0.7–0.9, with possible additional
contribution by CYP2C19 [1, 21–24, 35, 44]. However,
pharmacogenetic studies in humans have not revealed a
significant influence of CYP2C19 polymorphisms on the
clearance of tolbutamide in vivo [45–47]. Although these
studies could not rule out a minor role of CYP2C19, the
focus of the current studies is on tolbutamide as a CYP2C9
probe substrate. Therefore, to account for the non-CYP2C9
component of clearance, an additional hepatic clearance
component was included in the model to approximate 15%
of the total average clearance, but it was not assigned
specifically to CYP2C19. The retrograde calculator was
used to estimate the remaining CYP2C9-mediated clear-
ance, with a resulting population mean fm of 0.82, which is
consistent with the range of reported estimates described
above. The revised model parameters reproduced the
plasma pharmacokinetic profile adequately (Fig. 1). Using
this revised set of input parameters, the sulfaphenazole
interaction simulation was re-run, resulting in a predicted
AUC ratio (Table 3) consistent with the value reported by
Veronese et al. [27].
Evaluating drug interactions in patients with cancer
presents several challenges in addition to specific require-
ments that may arise due to a drug’s unique posology or
Table 5 Simulated and observed tolbutamide pharmacokinetics following a 2-hour intravenous infusion of tasisulam and 500 mg oral dose of
tolbutamide administered 2 h prior (Period 2) or 72 h following (Period 3) the start of infusion
Tolbutamide
GM (%CV or range)
Tolbutamide
(? Tasisulam—Period 2)
GM (%CV or range)
Tolbutamide
(? Tasisulam—Period 3)
GM (range)
Simulated Observed Simulated Observed (N = 4) Simulated Observed (N = 2)
CLpo (L/h) 0.84 (62%) 1.07 (29%) 0.14 (49%) 0.19 (20%) 0.15(49%) 0.19
Cmax (mg/L) 38.9 (35%) 39.6 (26%) 52.7 (35%) 39.8 (18%) 52.6 (35%) 48.0
AUC0–t (mgh/L) 594 (54%) 467 (29%) 3433 (42%) 2650 (19%) 3375(41%) 2690
Vdss/F (L) 8.1 (27%) 10.7 (21%) 8.1 (27%) 11.5 (30%) 8.1 (27%) 9.28
Tmax (h) 4.0 (3.8–4.2) 2.25 (2.0–3.0) 6.9 (3.5–11.0) 5.0 (1.5–8.0) 6.9 (3.5–11.0) 5.0
T1/2 (h) 7.0 (1.6–22) 6.9 (5.4–8.5) 31.6 (6.2–113) 42.7 (33.9–54.5) 31.6 (6.2–113) 34.7 (29.1–41.5)
AUC ratio NA NA 5.8 (5.4–6.2)a 5.7 (4.74–6.86) 5.7 (5.3–6.1) 5.8
Cmax ratio NA NA 1.35 (1.32–1.38)
a 1.0 (0.77–1.32) 1.35 (1.32–1.39) 1.2
%CV coefficient of variation, CLpo oral clearance, Cmax maximal plasma concentration, AUC0–t area under the curve from 0 to last time point,
Vdss/F apparent oral volume of distribution, Tmax time of maximal concentration, T1/2 half-life, NA not applicable, GM geometric mean
aValue in parentheses for AUC and Cmax ratios is 90% confidence interval
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pharmacokinetics. Due to the safety profile of tasisulam
and its stage of clinical development, DDI studies were
restricted to patients with advanced cancer for whom life
expectancy may be short. To be eligible for the study,
patients were required to have a life expectancy of at least
1–2 months to complete the minimum required sampling in
two study periods. The advanced cancer patient population
also presented a design challenge with respect to the need
to administer a probe drug in the absence of potentially
active treatment. As the delay between enrolment and
starting tasisulam was a maximum of 8 days, this proved
acceptable to investigators, patients, and ethics commit-
tees. In addition, patients with advanced cancer often take
many concomitant medications. However, to be able to
interpret the drug interaction data, concomitant medica-
tions involved in CYP2C9 pathways were excluded, pre-
senting another challenge to study design and enrolment.
Despite the hurdles to study design and conduct, the
tasisulam–tolbutamide interaction study clearly demon-
strated that tasisulam is a strong CYP2C9 inhibitor. A
challenge in designing these studies was the lack of data on
variability of substrates in patients with cancer. However,
the large effect size observed provided a conclusive answer
despite the limited sample size for the CYP2C9 study with
tolbutamide. Therefore, information from a small number
of patients proved extremely valuable in informing the
clinical development program. This might not be the case
for drugs with smaller predicted effect sizes, such as weak
or moderate CYP inhibitors.
The limitations on conducting extensive DDI studies in
patients with cancer highlight the value of PBPK models to
simulate clinical studies and refine clinical trial designs. In
fact, a majority of PBPK references in recent drug
approvals are related to anti-cancer drugs [5]. For a drug,
such as tasisulam, an accurate prediction of the magnitude
of DDI and resulting pharmacokinetic profile can both
ensure an adequate study design and help extrapolate
clinical data to a broader population or alternate dose
regimens. To illustrate this point, a top-down minimal
PBPK model was constructed for tasisulam and subse-
quently combined with the optimized tolbutamide model in
DDI simulations. The tasisulam PBPK model in a simu-
lated healthy population adequately reproduced the PK
observed after intravenous dosing in cancer patients, which
is characterized by a rapid initial distribution phase fol-
lowed by a long terminal half-life related to its low
intrinsic clearance and tight binding to plasma proteins.
Furthermore, replicating the JZAR clinical design in
SimCYP resulted in accurate prediction of the observed
fivefold increase in tolbutamide AUC. It is notable that the
clearance of tolbutamide in the uninhibited state was
slightly higher in the JZAR patients than reported values in
healthy volunteers, but the significance of this observation
is unknown. While the simulated trials predicted a 30%
increase in Cmax, no change in tolbutamide Cmax was
observed in this study; however, the measured concentra-
tions were within the lower 95th percentile of the predicted
values. It should also be noted that the patients included in
study JZAR were selected to have serum albumin
levels[30 g/L, resulting in plasma protein concentrations
within the range of normal values included in the simulated
healthy population. Since albumin concentrations are often
decreased in some patients with advanced cancer and both
tolbutamide and tasisulam are highly bound drugs, this
would need to be considered if extrapolating to a more
heterogeneous patient population [48]. Oncology-specific
SimCYP population models have been described that
account for observed differences in plasma proteins, age,
CYP expression, etc., [48, 49]. Such models might serve as
a useful framework for further predictions.
5 Conclusion
A middle-out PBPK model for tolbutamide was optimized
and verified for the prediction of CYP2C9-mediated DDI in
SimCYP. This model effectively reproduces the human
plasma pharmacokinetic profile of tolbutamide and accu-
rately predicts the magnitude of exposure changes when
co-administered with both oral and intravenous CYP2C9
inhibitors. The prediction of the observed fivefold increase
in tolbutamide AUC with co-administration of tasisulam in
cancer patients highlights the utility of mechanistic models
in navigating the challenges associated with conducting
clinical pharmacology studies in cancer patients. In the
current example, the simulated healthy volunteer popula-
tion appeared to be applicable to the small cancer patient
group studied. However, additional work is needed to
better understand the effect of different cancer disease
states on CYP-dependent drug clearance in larger popula-
tions [50].
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